JPH3 Gene

JPH3 Gene

Introduction

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">JPH3 Gene</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>JPH3</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Junctophilin 3</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>16q24.3</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>57338</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000125900</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q9Y2W5</td>
</tr>
<tr>
<td class="label">OMIM ID</td>
<td>605714</td>
</tr>
<tr>
<td class="label">Domain</td>
<td>Position</td>
</tr>
<tr>
<td class="label">N-terminal membrane-binding domain</td>
<td>AA 1-270</td>
</tr>
<tr>
<td class="label">Central alpha-helical domain</td>
<td>AA 271-500</td>
</tr>
<tr>
<td class="label">C-terminal coiled-coil</td>
<td>AA 501-638</td>
</tr>
<tr>
<td class="label">Protein</td>
<td>Expression Pattern</td>
</tr>
<tr>
<td class="label">JPH1</td>
<td>Skeletal muscle, heart</td>
</tr>
<tr>
<td class="label">JPH2</td>
<td>Cardiac muscle, neurons</td>
</tr>
<tr>
<td class="label">JPH3</td>
<td>Brain (striatum, cortex)</td>
</tr>
<tr>
<td class="label">JPH4</td>
<td>Testis, brain</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>Typical Presentation</td>
</tr>
<tr>
<td class="label">**Age of on

JPH3 Gene

Introduction

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">JPH3 Gene</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>JPH3</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Junctophilin 3</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>16q24.3</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>57338</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000125900</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q9Y2W5</td>
</tr>
<tr>
<td class="label">OMIM ID</td>
<td>605714</td>
</tr>
<tr>
<td class="label">Domain</td>
<td>Position</td>
</tr>
<tr>
<td class="label">N-terminal membrane-binding domain</td>
<td>AA 1-270</td>
</tr>
<tr>
<td class="label">Central alpha-helical domain</td>
<td>AA 271-500</td>
</tr>
<tr>
<td class="label">C-terminal coiled-coil</td>
<td>AA 501-638</td>
</tr>
<tr>
<td class="label">Protein</td>
<td>Expression Pattern</td>
</tr>
<tr>
<td class="label">JPH1</td>
<td>Skeletal muscle, heart</td>
</tr>
<tr>
<td class="label">JPH2</td>
<td>Cardiac muscle, neurons</td>
</tr>
<tr>
<td class="label">JPH3</td>
<td>Brain (striatum, cortex)</td>
</tr>
<tr>
<td class="label">JPH4</td>
<td>Testis, brain</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>Typical Presentation</td>
</tr>
<tr>
<td class="label">Age of onset</td>
<td>30-50 years (range 20-70)</td>
</tr>
<tr>
<td class="label">Initial symptoms</td>
<td>Motor: chorea, dystonia; cognitive: executive dysfunction</td>
</tr>
<tr>
<td class="label">Disease progression</td>
<td>Progressive over 15-20 years</td>
</tr>
<tr>
<td class="label">Neurological signs</td>
<td>Bradykinesia, rigidity, impaired coordination</td>
</tr>
<tr>
<td class="label">Psychiatric manifestations</td>
<td>Depression, anxiety, irritability</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">ASO therapy</td>
<td>Silence mutant JPH3 expression</td>
</tr>
<tr>
<td class="label">CRISPR editing</td>
<td>Correct repeat expansion</td>
</tr>
<tr>
<td class="label">RNA interference</td>
<td>Knockdown mutant protein</td>
</tr>
<tr>
<td class="label">AAV delivery</td>
<td>Express normal JPH3</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

Jph3 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

JPH3 (Junctophilin 3) is a gene that encodes a member of the junctophilin family of proteins, which are essential components of cellular junctional membrane complexes. Expansion of a CAG/CTG trinucleotide repeat in the JPH3 gene causes Huntington's disease-like 2 (HDL2), a rare autosomal dominant neurodegenerative disorder that clinically resembles Huntington's disease. [@wilburn2011]

Gene Information

Normal Function

JPH3 encodes Junctophilin-3, a membrane protein that plays critical roles in forming and maintaining junctional membrane complexes (JMCs) between the plasma membrane and the endoplasmic reticulum (ER). Key functions include:

• Calcium signaling: JPH3 participates in the formation of ER-plasma membrane contacts that facilitate calcium release from intracellular stores
• Synaptic function: Junctophilins are enriched at synaptic terminals, where they contribute to synaptic vesicle dynamics and neurotransmitter release
• Muscle function: In skeletal and cardiac muscle, JPH3 (and JPH2) are essential for excitation-contraction coupling
• Neuronal survival: JPH3 is expressed in [neurons](/entities/neurons) and may protect against excitotoxicity

• Striatum (medium spiny neurons)
• Cerebral [cortex](/brain-regions/cortex) (pyramidal neurons)
• [Hippocampus](/brain-regions/hippocampus)
• [Cerebellum](/brain-regions/cerebellum)

Disease Associations

Huntington's Disease-like 2 (HDL2)

HDL2 is caused by an expanded CAG/CTG trinucleotide repeat in the JPH3 gene. The clinical presentation is remarkably similar to Huntington's disease:

• Movement disorders: Chorea, dystonia, parkinsonism
• Cognitive decline: Executive dysfunction, memory impairment
• Behavioral changes: Depression, irritability, psychosis
• Progressive course: Disability typically develops within 15-20 years of onset

• Toxic protein aggregates: Translation of the expanded repeat produces toxic protein fragments
• RNA toxicity: CUG repeat-containing RNA forms foci that sequester RNA-binding proteins
• Loss of function: Reduced JPH3 protein may impair calcium homeostasis
• Gain of function: Aberrant protein interactions disrupt neuronal function

Other Neurological Conditions

• Huntington's disease: JPH3 expression is altered in HD, possibly as a compensatory mechanism
• Parkinson's disease: Reduced JPH3 expression reported in PD substantia nigra
• Schizophrenia: Genetic association studies suggest possible links
• Bipolar disorder: Some evidence of genetic involvement

Expression Pattern

JPH3 shows high expression in:

• Striatum (caudate nucleus and putamen)
• Cerebral cortex (layers 2-6)
• Hippocampus (CA1-CA4, dentate gyrus)
• [Thalamus](/brain-regions/thalamus)
• Cerebellum (granule cells and Purkinje cells)
• Substantia nigra (dopaminergic neurons)

Therapeutic Implications

Current therapeutic approaches for HDL2 include:

• Gene silencing: Antisense oligonucleotides targeting mutant JPH3 transcripts
• Small molecule therapies: Compounds targeting downstream pathways
• Symptomatic treatment: Similar to Huntington's disease management
• Calcium stabilizers: Agents that normalize calcium handling

Protein Structure and Function

Junctophilin-3 Protein Architecture

JPH3 encodes a protein of approximately 638 amino acids with the following domain organization:

The unique structure allows JPH3 to bridge the plasma membrane and ER, creating junctional membrane complexes (JMCs) essential for calcium signaling. The protein contains eight MAMP (membrane-attracting motif) domains that facilitate lipid bilayer contact.

Comparison with Other Junctophilins

Molecular Mechanisms of HDL2 Pathogenesis

Toxic Protein-Mediated Pathogenesis

The expanded CAG/CTG repeat in JPH3 leads to production of toxic polyglutamine (polyQ) and polyalanine (polyA) containing proteins:

RNA Toxicity Mechanisms

The CUG repeat-containing RNA transcripts form toxic structures:

• RNA foci formation: Sequestration of RNA-binding proteins (MBNL1, CELF1)
• Alternative splicing dysregulation: Aberrant splicing of downstream targets
• Translation interference: Reduced translation of normal JPH3 mRNA
• Drosha processing: Altered microRNA biogenesis

Calcium Homeostasis Disruption

JPH3 mutations lead to calcium dysregulation through multiple mechanisms:

Clinical Features of HDL2

Phenotypic Spectrum

HDL2 presents with a phenotype virtually indistinguishable from Huntington's disease:

Diagnostic Markers

• Genetic testing: Expanded CAG/CTG repeat in JPH3 (>41 repeats pathogenic)
• Brain imaging: Caudate atrophy, white matter abnormalities
• Neurophysiology: EEG changes, evoked potential abnormalities
• CSF biomarkers: Elevated tau, reduced amyloid markers

Therapeutic Development

Gene Therapy Approaches

Small Molecule Strategies

• Calcium modulators: Restore cellular calcium homeostasis
• Aggregation inhibitors: Prevent toxic protein oligomerization
• Neuroprotective agents: Support neuronal survival
• Symptomatic treatments: Manage chorea, psychiatric symptoms

Research Models

Animal Models

• JPH3 transgenic mice: Recapitulate motor and behavioral phenotypes
• Knock-in models: Express human JPH3 with expanded repeat
• Conditional knockouts: Tissue-specific deletion studies

Cellular Models

• iPSC-derived neurons: Patient-specific disease modeling
• Organoid systems: Three-dimensional brain tissue models
• CRISPR-edited cell lines: Isogenic controls for mechanism studies

References

External Links

• [NCBI Gene: JPH3](https://www.ncbi.nlm.nih.gov/gene/57338)
• [UniProt: JPH3](https://www.uniprot.org/uniprot/Q9Y2W5)
• [Ensembl: JPH3](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000125900)
• [OMIM: HDL2](https://www.omim.org/entry/605714)

References